Oliver Stötzer

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Cancer Biology, Oncology +16

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

Harpreet Wasan, Navesh Sharma, Volker Heinemann et al. · The Lancet Oncology · 2017 · 398 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Methods for isolation of cell-free plasma DNA strongly affect DNA yield

Michael Fleischhacker, Bernd Schmidt, Sabine Weickmann et al. · Clinica Chimica Acta · 2011 · 112 citations

Life Sciences, Genetics, Molecular Biology +11

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Rüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker et al. · Leukemia · 2020 · 92 citations · Full text

Life Sciences, Hematology, Oncology +16

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial

Stefan Boeck, K. Weigang-Köhler, Martin Fuchs et al. · Annals of Oncology · 2007 · 68 citations · Full text

Medicine, Oncology, Pharmacology +9